<DOC>
	<DOCNO>NCT02697058</DOCNO>
	<brief_summary>Study Part 1 : To assess safety tolerability , characterize pharmacokinetics ( PK ) BAX2398 combination 5-FU/calcium levofolinate Japanese patient . Study Part 2 : To compare efficacy BAX2398 combination 5-FU/calcium levofolinate versus 5-FU/calcium levofolinate assess Progression Free Survival ( PFS ) use Response Evaluation Criteria Solid Tumors , version 1.1 ( RECIST 1.1 ) .</brief_summary>
	<brief_title>Phase II BAX2398/5-FU/Calcium Levofolinate Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Participant ≥20 year age time screen . 2 . Histologically cytologically confirm adenocarcinoma exocrine pancreas 3 . Documented metastatic disease 4 . Metastatic disease least one measurable lesion define RECIST 1.1 guideline 5 . Documented disease progression prior gemcitabine gemcitabine contain therapy exclude irinotecan , locally advanced metastatic setting . Prior chemotherapy must stop least 21 day first dose . 6 . Karnofsky Performance Status ( KPS ) ≥70 7 . Adequate bone marrow reserve 8 . Adequate hepatic function 9 . Adequate renal function 10 . Normal ECG include Fridericia correct QT interval ( QTcF ) &lt; 440 m within 7 day prior first dose study drug 11 . Recovered effect prior surgery , radiotherapy antineoplastic therapy residual adverse event ( AEs ) Grade ≥2 . 12 . Able understand sign inform consent ( legal representative able ) 13 . If female childbearing potential , participant present negative pregnancy , agree employ adequate birth control measure study dose period 3 month follow last dose study drug . 14 . Participant willing able comply requirement protocol . 1 . Active uncontrolled central nervous system ( CNS ) metastases ; control CNS metastasis , patient steroid least 28 day prior start study therapy . 2 . History second malignancy last 5 year ; participant prior history insitu cancer basal squamous cell skin cancer eligible . Participants malignancy eligible continuously disease free least 5 year . 3 . Severe arterial thromboembolic event ( myocardial infarction , unstable angina pectoris , stroke ) less 6 month inclusion . 4 . Can stop medication potent CYP3A4 inducer within 2 week inhibitor within 1 week start treatment . 5 . Significant cardiac conduction abnormality , include history long QTcF syndrome and/or pacemaker . 6 . New York Heart Association ( NYHA ) Class III IV congestive heart failure , ventricular arrhythmia uncontrolled blood pressure . 7 . Active infection , include active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , HIV , unexplained fever &gt; 38.5°C screen visit first schedule day dose ( discretion investigator , patient tumor fever may enrol ) , investigator 's opinion might compromise patient 's participation trial affect study outcome . 8 . Known hypersensitivity component BAX2398 , liposomal product , fluoropyrimidines , calcium levofolinate . 9 . Any medical social condition deem investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . 10 . Participant expose investigational product ( IP ) within 30 day prior first dose study drug schedule participate another clinical study involve IP investigational device course study . 11 . Participant family member employee investigator . 12 . Participant pregnant lactating time enrollment . Lactating mother resume breast feed 30 day follow last dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>